Ovid Therapeutics (NASDAQ:OVID) versus Milestone Pharmaceuticals (NASDAQ:MIST) Critical Review

Ovid Therapeutics (NASDAQ:OVID) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Ovid Therapeutics and Milestone Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1	0	11	1	2.92
Milestone Pharmaceuticals	1	1	4	1	2.71

Ovid Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 177.78%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 887.35%. Given Milestone Pharmaceuticals’ higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Ovid Therapeutics.

Valuation & Earnings

This table compares Ovid Therapeutics and Milestone Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$1.58 million	266.48	-$17.41 million	($0.31)	-6.97
Milestone Pharmaceuticals	$2.34 million	34.44	-$63.06 million	($0.69)	-0.94

Ovid Therapeutics has higher earnings, but lower revenue than Milestone Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ovid Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

Institutional & Insider Ownership

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Ovid Therapeutics and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	N/A	-23.64%	-20.52%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Summary

Ovid Therapeutics beats Milestone Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.